SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity

Area of Science:

• Neuropharmacology
• Dopamine Receptor Research

Background:

• Dopamine receptors, particularly D1-like and D2-like subtypes, play crucial roles in various neurological functions.
• Selective modulation of dopamine receptor subtypes is a key strategy in developing treatments for central nervous system disorders.

Purpose of the Study:

• To characterize the pharmacological profile of SDZ PSD 958, a novel benzo[g]quinoxaline derivative.
• To determine the selectivity and functional activity of SDZ PSD 958 as a dopamine D1 receptor antagonist.

Main Methods:

• Radioligand binding assays using [3H]SCH23390 and [3H]spiperone to assess receptor affinity.
• Functional assays evaluating the effects of SDZ PSD 958 on D1 receptor-mediated behaviors in animal models (e.g., apomorphine-induced rearing, novelty-induced locomotion).

Main Results:

• SDZ PSD 958 demonstrated high affinity for D1-like receptors (D1, D5) with pKi values of 9.7-9.8.
• It exhibited at least 400-fold lower activity at D2-like receptors (D2, D4).
• Functional tests confirmed D1 receptor antagonist properties, inhibiting D1 agonist-induced behaviors without inducing catalepsy or significantly affecting D2-mediated behaviors.

Conclusions:

• SDZ PSD 958 is a potent and orally active selective dopamine D1 receptor antagonist.
• Its pharmacological profile suggests preferential inhibition of dopamine systems in the limbic system.
• SDZ PSD 958 represents a promising candidate for further investigation in neurological and psychiatric disorders involving D1 receptor pathways.